Structure determination of enalapril maleate Form II from high-resolution X-ray powder diffraction data

被引:31
作者
Kiang, YH
Huq, A
Stephens, PW
Xu, W
机构
[1] Merck & Co Inc, Merck Res Labs, Pharmaceut Res & Dev, Collegeville, PA 19426 USA
[2] SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA
基金
美国能源部;
关键词
enalapril maleate; polymorphism; crystal structure determination; X-ray powder diffraction (XRPD) pattern; Monte-Carlo/simulated annealing;
D O I
10.1002/jps.10430
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The crystal structure of polymorphic Form II of enalapril maleate, a potent angiotensin-converting enzyme inhibitor, was determined from high-resolution X-ray diffraction data using the direct space method. Enalapril maleate Form II crystallizes in space group P2(1)2(1)2(1), Z = 4, with unit cell parameters a = 33.9898(3) Angstrom, b = 11.2109(1) Angstrom, c = 6.64195(7) Angstrom, and V = 2530.96(5) Angstrom(3). By treating the molecules as rigid bodies and using the bond lengths and angles obtained from the X-ray single crystal structures of Form I, which were solved almost 20 years ago, the total degrees of freedom of enalapril maleate were reduced from 25 to 12. This reduction in total degrees of freedom allowed the simulated annealing to complete within a reasonable computation time. In the crystal structure of Form II, the crystal packing, hydrogen-bonding pattern, and conformation of enalapril maleate resemble those in the structure of Form I. The crystal packing and conformation of enalapril maleate in the two polymorphic forms may explain the similarity of the thermal properties, C-13 nuclear magnetic resonance, Fourier transform infrared, and Raman spectra of Forms I and II. In both structures, the conformations of the main peptide chains, which are considered responsible for binding the active angiotensin-converting enzyme sites, remain largely unchanged. Lattice energy calculation showed that Form 11 is slightly more stable than Form I by 3.5 kcal/mole. (C) 2003 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:1844 / 1853
页数:10
相关论文
共 39 条
[11]  
2-C
[12]   PowderSolve -: a complete package for crystal structure solution from powder diffraction patterns [J].
Engel, GE ;
Wilke, S ;
König, O ;
Harris, KDM ;
Leusen, FJJ .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1999, 32 :1169-1179
[13]  
Frisch MJ., 1992, GAUSSIAN 92 DFT REVI
[14]   SQ-14,225 - 1-(D-3-MERCAPTO-2-METHYLPROPIONYL)-L-PROLINE [J].
FUJINAGA, M ;
JAMES, MNG .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 1980, 36 (DEC) :3196-3199
[15]   Ab initio crystal structure determination of three pharmaceutical compounds from X-ray powder diffraction data [J].
Giovannini, J ;
Perrin, MA ;
Louër, D ;
Leveiller, F .
EPDIC 7: EUROPEAN POWDER DIFFRACTION, PTS 1 AND 2, 2001, 378-3 :582-587
[16]   PHARMACEUTICAL APPLICATIONS OF POLYMORPHISM [J].
HALEBLIAN, J ;
MCCRONE, W .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1969, 58 (08) :911-+
[17]  
In Y., 1986, CHEM COMMUN, P473
[18]  
IP DP, 1986, INT J PHARM, V28, P83
[19]   Structure determination of a steroid directly from powder diffraction data [J].
Kariuki, BM ;
Psallidas, K ;
Harris, KDM ;
Johnston, RL ;
Lancaster, RW ;
Staniforth, SE ;
Cooper, SM .
CHEMICAL COMMUNICATIONS, 1999, (17) :1677-1678
[20]  
KITAIGOROSKII AI, 1961, ORGANIC CHEM CRYSTAL